Literature DB >> 8496570

[Chronic blepharoconjunctivitis during a treatment with acitretin (Soriatane)].

P Denis1, J P Nordmann, P Saiag, S Liotet, L Laroche, H Saraux.   

Abstract

We report external ocular side effects after treatment with acitretin, a new synthetic vitamin A analogue and the main metabolite of etretinate. A patient treated with 20-25 mg/day of acitretin for psoriasis suffered from chronic blepharoconjunctivitis. Schirmer tests, tear lysozyme were normal while rose bengal and fluorescein staining disclosed epithelial punctate defects and tear break-up time was shortened. Meibomian glands of the lower lid were photographed with transillumination and appeared atrophic. Conjunctival cytology and biopsy showed snake-like chromatine appearance, keratinized epithelial cells and some lymphocytes infiltrates. Accessory salivary gland histological aspects were nonspecific. There was a clear relationship between restarting the acitretin therapy and recurrence of ocular symptoms. Acitretin, like other retinoids, may induce or exacerbate blepharoconjunctivitis in patients with psoriasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496570

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  3 in total

1.  Rapid improvement of chronic interstitial keratitis with acitretin.

Authors:  M Labetoulle; H Offret; I Bournerias; E Frau
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 2.  The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland.

Authors:  Erich Knop; Nadja Knop; Thomas Millar; Hiroto Obata; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

3.  Changes in gene expression in human meibomian gland dysfunction.

Authors:  Shaohui Liu; Stephen M Richards; Kristine Lo; Mark Hatton; Aaron Fay; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-25       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.